SEZ6-targeting antibody−drug conjugate ABBV-706 in advanced small cell lung cancer and solid tumors: a phase 1 trial - Scorecard - MDSpire

SEZ6-targeting antibody−drug conjugate ABBV-706 in advanced small cell lung cancer and solid tumors: a phase 1 trial

  • By

  • Lauren Averett Byers

  • Byoung Chul Cho

  • Alissa J. Cooper

  • Anne C. Chiang

  • Ji-Youn Han

  • Muhammad Furqan

  • Afshin Dowlati

  • Daniel Morgensztern

  • Kyriakos P. Papadopoulos

  • Noura J. Choudhury

  • María Vieito

  • Jair Bar

  • Joo-Hang Kim

  • Wallace Akerley

  • Tae Min Kim

  • Young-Chul Kim

  • Luis Paz-Ares

  • Myung-Ju Ahn

  • Hiroshi Yokouchi

  • Darius Meiman

  • Wijith Munasinghe

  • Oluwadamilola Ogunyankin

  • Nadine Jahchan

  • Song Wang

  • Cristiano Ferlini

  • Randy R. Robinson

  • Frederick J. Kohlhapp

  • Tammy Palenski

  • Guillermo Rivell

  • Pooja Hingorani

  • Sreenivasa Chandana

  • June 1, 2026

  • 0 min

Share

Clinical Scorecard: Phase 1 Trial of ABBV-706, an Antibody-Drug Conjugate Targeting SEZ6, in Patients with Advanced Small Cell Lung Cancer and Other Solid Tumors

At a Glance

CategoryDetail
ConditionAdvanced Small Cell Lung Cancer (SCLC)
Key MechanismsABBV-706 is an antibody-drug conjugate targeting SEZ6, inducing DNA damage and apoptosis via Top1i release.
Target PopulationPatients with relapsed/refractory SCLC and other solid tumors.
Care SettingPhase 1 clinical trial.

Key Highlights

  • ORR

Guideline-Based Recommendations

Diagnosis

    Management

    • I
    • n
    • c
    • l
    • u
    • d
    • e
    • s
    • p
    • e
    • c
    • i
    • f
    • i
    • c
    • c
    • h
    • e
    • m
    • o
    • t
    • h
    • e
    • r
    • a
    • p
    • y
    • r
    • e
    • g
    • i
    • m
    • e
    • n
    • s
    • l
    • i
    • k
    • e
    • p
    • l
    • a
    • t
    • i
    • n
    • u
    • m
    • -
    • e
    • t
    • o
    • p
    • o
    • s
    • i
    • d
    • e
    • .

    Monitoring & Follow-up

      Risks

        Patient & Prescribing Data

        Adult patients with advanced solid tumors, specifically those with R/R SCLC.

        ABBV-706 administered intravenously every three weeks, with a focus on safety and efficacy.

        Clinical Best Practices

        • Consider novel therapies like ABBV-706 for patients with limited treatment options.
        • Monitor for safety and efficacy in patients receiving ABBV-706 monotherapy.

        Related Resources & Content

        Original Source(s)

        SEZ6-targeting antibody−drug conjugate ABBV-706 in advanced small cell lung cancer and solid tumors: a phase 1 trial

        • by Lauren Averett Byers, Byoung Chul Cho, Alissa J. Cooper, Anne C. Chiang, Ji-Youn Han, Muhammad Furqan, Afshin Dowlati, Daniel Morgensztern, Kyriakos P. Papadopoulos, Noura J. Choudhury, María Vieito, Jair Bar, Joo-Hang Kim, Wallace Akerley, Tae Min Kim, Young-Chul Kim, Luis Paz-Ares, Myung-Ju Ahn, Hiroshi Yokouchi, Darius Meiman, Wijith Munasinghe, Oluwadamilola Ogunyankin, Nadine Jahchan, Song Wang, Cristiano Ferlini, Randy R. Robinson, Frederick J. Kohlhapp, Tammy Palenski, Guillermo Rivell, Pooja Hingorani, Sreenivasa Chandana

        • June 1, 2026

        Related Content

        Application of patient-derived organotypic tumor spheroids to guide combination immunotherapy for advanced HCC: a case report

        Current status and trends of immune-related adverse events in lung cancer treated with immune checkpoint inhibitors: a bibliometric analysis of the past decade (2016–2025)

        From monoclonals to bispecific T cell engagers: the evolving antibody-based therapy landscape in acute myeloid leukemia